PET and PET/CT in Management of the Lymphomas

Radiologic Clinics of North America

Volumn 45, Issue 4, 2007, Pages 689-696

  Podoloff, Donald A ^a   Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547731496     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2007.05.008     Document Type: Review

References (24)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
2. Weir R, Thun MJ, Hankey BF et al. SEER cancer statistics review 1975-2000. Bethesda (MD): National Cancer Institute.
3. Bastion Y., Berger F., Bryon P.A., et al. Follicular lymphomas; assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol Suppl 2 (1991) 123-129
4. Haliday T., and Baxter G. Lymphoma. Pictorial review II. Eur Radiol 13 (2003) 1224-1234
5. Hustinx R., Jerusalem G., Fillet G., et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 16 (2001) 297-304
6. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
7. Bangerter M., Moog F., Buchman I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9 (1998) 1117-1122
8. Young C.S., Young B.L., and Smith S.M. Staging Hodgkin's disease with 18-FDG PET. Clin Positron Imaging 1 (1998) 161-164
9. Foo S.S., Mitchell P.L., Berlangieri S.U., et al. Positron emission tomography scanning in the assessment of patients with lymphoma. Int Med J 34 (2004) 388-397
10. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F-FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is 18F-FDG-PEY a valid alternative to conventional diagnostic methods?. J Clin Oncol 192 (2001) 414-419
11. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
12. Zinzani P.L., Fanti S., Battista G., et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 91 (2004) 850-854
13. Guay C., Lepine M., Verreault J., et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for post treatment evaluation. J Nucl Med 44 (2003) 1225-1231
14. Zinzani P.L., Chierichetti F., Zompatori M., et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 43 (2002) 1239-1243
15. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Hematol 115 (2001) 793-800
16. Dittmann H., Sokler M., Kollmannsberger C., et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8 (2001) 1393-1399
17. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with 18F-fluorodeoxuglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
18. Hart D.P., Avivi I., Thomson K.J., et al. Use of 18F-FDG positron emission tomography following allergenic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol 128 (2005) 824-829
19. Roelke U., and Leenders K.L. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 43 (1999) 231-236
20. Castellucci P., Zinzani P., Nanni C., et al. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm 19 (2004) 606-612
21. Allen-Auerbach M., Quon A., Weber W.A., et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6 (2004) 411-416
22. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin's lymphoma and Hodgkin's disease: co-registered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 (2004) 823-829
23. Tatsumi M., Cohade C., Nakamoto Y., et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237 (2005) 1038-1045
24. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hemat 52 (2004) 19-32